ReviewOncolytic virotherapy2018
Development and applications of oncolytic Maraba virus vaccines.
Review in Oncolytic virotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours
A Phase 1/2 Trial of MG1 Maraba Expressing MAGE-A3 (MG1-MAGEA3), With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)
Who cites it
34 citing papers in PubMed, 48 citations in OpenAlex.
- Overcoming Barriers to Clinical Translation: MG1 Maraba Virus as an Emerging Platform for Oncolytic Immunotherapy.Viruses · 2026Review
- Gnostic and agnostic immunotherapy by tropism-retargeted herpes simplex virus without direct tumor treatment.Journal for immunotherapy of cancer · 2025Article
- Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.Nature biomedical engineering · 2025Article
- Turning the tide: harnessing vaccines and viruses to fight cancer.Immunotherapy advances · 2025Review
- Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent.Molecular cancer therapeutics · 2024Article
- Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.Nature protocols · 2024Review
- Investigating the effect of reduced temperatures on the efficacy of rhabdovirus-based viral vector platforms.The Journal of general virology · 2024Article
- Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.Journal for immunotherapy of cancer · 2024Article
- Review
- Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment.Journal of cancer metastasis and treatment · 2023Article
- Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers.Frontiers in immunology · 2023Review
- Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy.Pathogens (Basel, Switzerland) · 2022Review
- Oncolytic viruses in melanoma.Frontiers in bioscience (Landmark edition) · 2022Review
- Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?Frontiers in immunology · 2022Review
- Role of Adenoviruses in Cancer Therapy.Frontiers in oncology · 2022Review
- Article
- Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma.The Journal of experimental medicine · 2021Article
- A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.Nature communications · 2021Article
- Current status of intralesional agents in treatment of malignant melanoma.Annals of translational medicine · 2021Review
- Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.Journal of hematology & oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic activity of the MG1 strain of the Maraba vesiculovirus has proven efficacy in numerous preclinical cancer models, and relied not only on a direct cytotoxicity but also on the induction of both innate and adaptive antitumor immunity. To further expand tumor-specific T-cell effector and long-lasting memory compartments, we introduced the MG1 virus in a prime-boost cancer vaccine strategy. To this aim, a replication-incompetent adenoviral [Ad] vector together with the oncolytic MG1 have each been armed with a transgene expressing a same tumor antigen. Immune priming with the Ad vaccine subsequently boosted with the MG1 vaccine mounted tumor-specific responses of remarkable magnitude, which significantly prolonged survival in various murine cancer models. Based on these promising results, we validated the safety profile of the Ad:MG1 oncolytic vaccination strategy in nonhuman primates and initiated clinical investigations in cancer patients. Two clinical trials are currently under way (NCT02285816; NCT02879760). The present review will recapitulate the discoveries that led to the development of MG1 oncolytic vaccines from bench to bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.